Burt Adelman

Burt Adelman, MD, is Chairman and co-founder of Clear Creek Bio. Burt graduated from Cornell University Medical College in 1976. He served as House Officer and Medical Resident at the Peter Bent Brigham Hospital from where he completed his hematology fellowship. Burt was a full-time faculty member for 10 years: first at Harvard Medical School and then the Medical College of Virginia. In 1991, he joined Biogen and held leadership roles, including Executive Vice President of Research and Development and Executive Vice President for Portfolio Strategy. At Biogen, Burt led development efforts for Angiomax (bivalarudin) for anticoagulation during angioplasty, Avonex (interferon beta) for multiple sclerosis, Amevive (alefecept) for psoriasis, and Tysabri (natalizumab) for multiple sclerosis. Burt retired from Biogen in 2007 and was most recently Executive Vice President Research and Development and Chief Medical Officer at Dyax Corp where he led the successful development of lanadelumab, a breakthrough drug for the prevention of acute attacks of hereditary angioedema. Dyax was sold to Shire in 2016 for $6.5 billion. Burt was a board member of Syntimmune through its acquisition by Alexion for $1.2 billion.